Holen Sie sich die Stockscreener-App
14.37
1.13%
0.16
Handel nachbörslich:
14.37
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt AUPH?
Forum
Prognose
Aktiensplit
Aurinia Pharmaceuticals Inc Aktie (AUPH) Neueste Nachrichten
[SCHEDULE 13D/A] Aurin... - Stock Titan
AUPH stock rallies after CEO shake-up: Retail bulls bet on turnaround - MSN
AUPH SEC FilingsAurinia Pharmace 10-K, 10-Q, 8-K Forms - Stock Titan
Aurinia names board chair Kevin Tang as new CEO By Investing.com - Investing.com Canada
Mutiny At Aurinia Pharmaceuticals? Biotech Rallies On C-Suite Shake-Up - Investor's Business Daily
Aurinia appoints Kevin Tang as CEO with zero compensation By Investing.com - Investing.com India
Why Aurinia Pharmaceuticals stock is surging Monday morning - MSN
Aurinia Reshapes C-Suite as Investor Kevin Tang Takes CEO Role Without Pay - TipRanks
Aurinia Pharmaceuticals Announces New CEO and Leadership Team Amid Continued Growth in Autoimmune Disease Therapies 1 - Minichart
Aurinia appoints Kevin Tang as CEO with zero compensation - Investing.com
MKT Capital Applauds Aurinia Pharmaceuticals’ Management Transition - FinancialContent
Why Aurinia Pharmaceuticals Stock Is Surging Monday Morning - Benzinga
Aurinia Reshapes Executive Team as Board Chair Kevin Tang Becomes CEO - TipRanks
Aurinia Pharmaceuticals Inc. Appoints Michael Hearne as Chief Financial Officer - marketscreener.com
Aurinia Pharmaceuticals Inc. Announces Executive Appointments - marketscreener.com
Aurinia Pharmaceuticals Inc. Announces Chief Executive Officer Changes - marketscreener.com
Aurinia names board chair Kevin Tang as new CEO - Investing.com
Aurinia appoints Kevin Tang as CEO and Ryan Cole as COO - TradingView
Aurinia (NASDAQ: AUPH) installs Kevin Tang as CEO amid broad C-suite exits - Stock Titan
Aurinia Announces Management Transition - The Joplin Globe
(AUPH) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Aurinia names Kevin Tang as new CEO, retail bet on turnaround | Tap to know more | Inshorts - Inshorts
Aurinia raises 2025 revenue outlook to $270M as LUPKYNIS accelerates market penetration - MSN
Investors - Aurinia Pharmaceuticals Inc.
AUPH Stock Rallies After CEO Shake-Up: Retail Bulls Bet On Turnaround - Stocktwits
Aurinia Pharmaceuticals (NASDAQ:AUPH) Stock Passes Below 200-Day Moving AverageHere's What Happened - MarketBeat
Aurinia Pharmaceuticals (AUPH) stock drops after strong quarter, softer forward revenue targets - MSN
AUPH stock gains on Aurinia Pharma’s Q4 beat, but 2026 guidance misses estimates - MSN
Buybacks Report: What dividend growth rate does Aurinia Pharmaceuticals Inc offerMarket Activity Summary & Verified Momentum Stock Ideas - baoquankhu1.vn
Market Trends: Will Aurinia Pharmaceuticals Inc benefit from government policySell Signal & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
Is Aurinia Pharmaceuticals (AUPH) Pricing Reflect Long Term Value After 71% One Year Gain - Yahoo Finance
Responsive Playbooks and the AUPH Inflection - Stock Traders Daily
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Aurinia Pharmaceuticals (NASDAQ:AUPH) Stock Passes Below 50-Day Moving AverageShould You Sell? - MarketBeat
Aurinia Pharma’s Wild Ride: What AUR’s Lupus Bet Means For You - AD HOC NEWS
A Look At Aurinia Pharmaceuticals (AUPH) Valuation After Strong Growth And Optimistic 2026 Guidance - simplywall.st
The Bull Case For Aurinia Pharmaceuticals (AUPH) Could Change Following Strong 2025 Results And Upbeat 2026 Outlook - Sahm
Aurinia Pharmaceuticals Earnings Strength And Valuation Gap Attract Investor Attention - Sahm
Implied Volatility Surging for Aurinia Pharmaceuticals Stock Options - MSN
Aug Breakouts: Why is Aurinia Pharmaceuticals Inc stock going upExit Point & Daily Oversold Bounce Ideas - baoquankhu1.vn
Aurinia Pharmaceuticals: Waiting For Another Opportunity (Downgrade) (NASDAQ:AUPH) - Seeking Alpha
Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent Business Progress - Zenopa
Aurinia Pharmaceuticals (NASDAQ:AUPH) Director Buys $7,224,981.61 in Stock - MarketBeat
Aurinia Pharmaceuticals Inc (AUPH): Investor Outlook Reveals 19.63% Potential Upside - DirectorsTalk Interviews
Tang Capital LPs tied to Aurinia (NASDAQ: AUPH) buy 900K shares - Stock Titan
Assessing Aurinia Pharmaceuticals (AUPH) Valuation After Recent Share Price Swings - simplywall.st
Tang Capital boosts Aurinia (AUPH) stake to 9.2% ownership - Stock Titan
Aurinia (NASDAQ: AUPH) CFO gets stock, options; covers tax bill - Stock Titan
Aurinia (AUPH) COO receives stock grants and settles taxes with shares - Stock Titan
Aurinia (NASDAQ: AUPH) CEO receives major option grant and withholds shares for taxes - Stock Titan
Aurinia (AUPH) CMO awarded new stock options and share grant - Stock Titan
Aurinia (AUPH) EVP gets stock awards and has shares withheld for taxes - Stock Titan
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Passes Key Growth Screener from "The Little Book That Makes You Rich" - ChartMill
GSA Capital Partners LLP Trims Stake in Aurinia Pharmaceuticals Inc $AUPH - MarketBeat
Should Aurinia’s Surging 2025 Earnings and Upbeat 2026 Outlook Require Action From Aurinia (AUPH) Investors? - Yahoo Finance
Aurinia’s LUPKYNIS Strength And Aritinercept Progress Versus Valuation Signals - simplywall.st
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):